Cargando…

The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study

As a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate favorably modulates dyslipidemia and inflammation markers, which are associated with cardiovascular risk. To determine whether variation in the PPARα receptor gene was associated with lipid and inflammatory marker res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frazier-Wood, A.C., Ordovas, J.M, Straka, R.J., Hixson, J.E., Borecki, I.B., Tiwari, H.K., Arnett, D.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410976/ https://www.ncbi.nlm.nih.gov/pubmed/22547144 http://dx.doi.org/10.1038/tpj.2012.9

Ejemplares similares

Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study
por: Das, Mithun, et al.
Publicado: (2015)

The association between LRP1 and chylomicron uptake after the ingestion of a high-fat meal
por: Frazier-Wood, AC, et al.
Publicado: (2012)

An Exome-Wide Sequencing Study of the GOLDN Cohort Reveals Novel Associations of Coding Variants and Fasting Plasma Lipids
por: Geng, Xin, et al.
Publicado: (2019)

Modification effect of fenofibrate therapy, a longitudinal epigenomic-wide methylation study of triglycerides levels in the GOLDN study
por: Wei, Runmin, et al.
Publicado: (2018)

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate
por: Frazier-Wood, Alexis C., et al.
Publicado: (2014)

Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma adiponectin concentrations in the GOLDN Study
por: Rasmussen-Torvik, Laura J, et al.
Publicado: (2009)

Genomics of Post-Prandial Lipidomic Phenotypes in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study
por: Irvin, Marguerite R., et al.
Publicado: (2014)

High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional study
por: Wojczynski, Mary K, et al.
Publicado: (2011)

Family-based genome-wide association of inflammation biomarkers and fenofibrate treatment response in the GOLDN study
por: Das, Sarmistha, et al.
Publicado: (2018)

Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate
por: Aslibekyan, Stella, et al.
Publicado: (2012)

Metabolic and inflammatory biomarkers are associated with epigenetic aging acceleration estimates in the GOLDN study
por: Irvin, Marguerite R., et al.
Publicado: (2018)

Age and sex are associated with the plasma lipidome: findings from the GOLDN study
por: Slade, Emily, et al.
Publicado: (2021)

Integrating epigenetic, genetic, and phenotypic data to uncover gene-region associations with triglycerides in the GOLDN study
por: Romanescu, Razvan G., et al.
Publicado: (2018)

TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate
por: Kabagambe, Edmond K, et al.
Publicado: (2009)

A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies
por: Hidalgo, Bertha A., et al.
Publicado: (2021)

Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study
por: Das, Mithun, et al.
Publicado: (2016)

The Relation between Erythrocyte Trans Fat and Triglyceride, VLDL- and HDL-Cholesterol Concentrations Depends on Polyunsaturated Fat
por: Kabagambe, Edmond K., et al.
Publicado: (2012)

Preliminary Evidence for an Association between LRP-1 Genotype and Body Mass Index in Humans
por: Frazier-Wood, Alexis C., et al.
Publicado: (2012)

Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction
por: Woo, Yeongmin, et al.
Publicado: (2018)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data
por: Yu, Jih-Chang, et al.
Publicado: (2018)

Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels
por: Sarnowski, Chloé, et al.
Publicado: (2018)

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy
por: van Bochove, Kees, et al.
Publicado: (2012)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

Profile of serum bile acids in non-cholestatic volunteers: gender-related differences in response to fenofibrate
por: Trottier, J., et al.
Publicado: (2011)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

A clustering analysis of lipoprotein diameters in the metabolic syndrome
por: Frazier-Wood, Alexis C, et al.
Publicado: (2011)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
por: Rolland, Benjamin, et al.
Publicado: (2012)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
por: Zhou, Tong, et al.
Publicado: (2022)

Activation of PPARα by Fenofibrate Attenuates the Effect of Local Heart High Dose Irradiation on the Mouse Cardiac Proteome
por: Azimzadeh, Omid, et al.
Publicado: (2021)

The impact of alcoholic drinks and dietary factors on epigenetic markers associated with triglyceride levels
por: Lai, Chao-Qiang, et al.
Publicado: (2023)

Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials
por: Ye, Jiatao, et al.
Publicado: (2011)

Treatment with PPARα Agonist Clofibrate Inhibits the Transcription and Activation of SREBPs and Reduces Triglyceride and Cholesterol Levels in Liver of Broiler Chickens
por: Zhang, Lijun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gms9jav711l8j27nqd22cdrorb